Abingworth Management
Carlyle acquires life sciences investor Abingworth
Deal follows EQT's acquisition of LSP in November 2021 as asset managers look for greater specialisation
Abingworth Clinical Co-Development Fund 2 closes on $582m
ACCD 2 finances the development of late-stage clinical programmes of pharmaceutical and biotechnology companies
Biotech market provides dose of optimism
In the past year, the biotech market has seen buoyant activity, reaching record levels of investments
Abingworth Bioventures 8 closes on $465m
ABV 8 targets companies developing innovative therapeutics, with investments across the US, UK and continental Europe
Abingworth appoints MVM's Muralidhar
Muralidhar will work with the team in London, Boston and Melo Park to source new investments
Abingworth closes 12th fund on $315m
ABV VII will follow the same strategy as its predecessor, investing in early- and late-stage deals
PE-backed Wilson Therapeutics in SEK 7.1bn trade sale
Alexion Pharmaceuticals announces a public cash offer to acquire Wilson for SEK 232 per share
Abingworth raises $115m for seventh Bioventures fund
ABV VII will be the GP's 11th venture-focused fund, and is understood to be targeting $400m
VC-backed GenSight Biologics raises €40m in IPO
Flotation on Euronext Paris gives the biotech a market cap of €149m
Abingworth closes maiden co-development fund on $105m
VC's 11th vehicle will be used for five to six co-development deals over the next three years
Kesios raises £19m series-A from Abingworth et al.
Kesios span out of Imperial College in July 2012
Abingworth recruits Chu as partner
Hire comes three months after firm concluded management succession
Abingworth completes succession
Bunting steps down as managing partner to become chairperson
Gimv et al. exit listed Prosensa
Sale resulted in 4.6x return on historial investment cost for Gimv
VC-backed Pixium floats with €100m market cap
Company sold 4.2 million shares at 828 euro cents apiece
VC-backed Pixium plans flotation
Company could raise up to €36.6m in IPO
Abingworth, MVM lead $40m Wilson round
Previous investor HealthCap joins round
Abingworth closes 10th fund on £225m
Life sciences and healthcare investor Abingworth has held a final close for Abingworth Bioventures VI on £225m, exceeding its £200m target.
VC-backed Lombard to leave AIM for Nasdaq
Lombard Medical Technologies, a London-based medical devices company backed by Abingworth Management and MVM Life Science Partners, is planning to delist from the London Stock Exchange’s AIM and relist on the Nasdaq.
Sofinnova leads €15m round for Pixium
Sofinnova Partners has led a €15m extension of Pixium Vision’s two-part series-A round alongside BPI France and existing investors Omnes Capital and Abingworth Management.
Sector focus: An outbreak of biotech IPOs
Biotech IPOs
VC-backed Prosensa raises $78m in IPO
Dutch biotechnology company Prosensa Holding, which is backed by a consortium of venture capital firms, has listed on the Nasdaq Global Select Market in an IPO valuing the business at $408m.
Venture's Olympic performance
Venture's Olympic performance
Syntaxin receives £18m investment
Lundbeckfond Ventures, Seventure and Ipsen have taken part in a series-C round of financing for biopharmaceutical company Syntaxin.